Non-Opioid Pain Treatments in 2026: A Comprehensive Guide for PI Attorneys

James Wong — Founder & CEO, LienScripts | March 26, 2026 | 7 min read

The non-opioid pain treatment landscape in 2026 includes Journavx (suzetrigine), gabapentinoids, SNRIs, prescription topicals, and CGRP agents. Each drug class documents a different pain mechanism and supports PI case value in distinct ways. This guide covers every non-opioid option available to your clients.

The non-opioid pain treatment landscape in 2026 is broader and more clinically sophisticated than at any point in the past two decades. PI attorneys now encounter client medication records that include Journavx (suzetrigine), gabapentinoids, SNRIs, prescription topical analgesics, CGRP migraine agents, and targeted muscle relaxants — each prescribed for a specific pain mechanism and each contributing distinct evidentiary value to the demand package.

• Journavx (suzetrigine), FDA-approved January 2025, is the first Nav1.8-selective blocker for acute moderate-to-severe pain — the most significant new analgesic mechanism since the 1990s
• Gabapentinoids (gabapentin, pregabalin) remain the standard for neuropathic pain from nerve damage, and dose escalation documents injury severity
• SNRIs (duloxetine, venlafaxine) treat both chronic pain and co-occurring PTSD/depression — dual-purpose prescriptions that document multiple injury dimensions
• CGRP agents (Aimovig, Ajovy, Emgality, Qulipta, Nurtec) are prescribed for post-traumatic migraine, with monthly injectable costs that add significantly to pharmacy specials
• LienScripts covers all non-opioid pain medications on pharmacy lien and generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report for every case

Journavx (Suzetrigine): The 2025 Breakthrough

Journavx is the first analgesic approved with a genuinely new mechanism of action since the introduction of COX-2 inhibitors in the late 1990s. It selectively blocks Nav1.8 voltage-gated sodium channels expressed in peripheral pain-sensing neurons, interrupting pain signal transmission at the source without affecting the brain or heart (FDA NDA 218049, January 2025).

Clinical profile:

• Indicated for moderate-to-severe acute pain in adults
• Dosed 50mg twice daily (optional 100mg loading dose)
• Not a controlled substance; no abuse potential
• No cognitive impairment, sedation, or respiratory depression
• Brand-name only (Vertex Pharmaceuticals); no generic available

Settlement value impact: A Journavx prescription documents acute pain at the moderate-to-severe threshold. Because it is non-opioid and non-controlled, defense counsel cannot characterize the prescription as excessive or addiction-related. The brand-name cost contributes meaningfully to pharmacy specials.

[!KEY] According to James Wong, PharmD, founder of LienScripts, "In 2026, attorneys should expect to see Journavx in an increasing percentage of post-accident and post-surgical medication records. Understanding what this prescription means — and how it strengthens the demand — is essential for maximizing case value."

Gabapentinoids: Gabapentin and Pregabalin

Gabapentinoids have been the standard neuropathic pain treatment for over a decade and remain foundational in PI medication regimens where nerve damage is present.

Gabapentin (Neurontin):

• Titrated from 300mg/day up to 3600mg/day
• Dose escalation over weeks documents treatment resistance and pain severity
• FDA-approved for postherpetic neuralgia; widely used off-label for traumatic neuropathic pain (Wiffen et al., Cochrane Database Syst Rev, 2017)

Pregabalin (Lyrica):

• More potent than gabapentin with more predictable absorption
• Dosed 150-600mg/day
• FDA-approved for neuropathic pain, fibromyalgia
• Schedule V controlled substance (mild abuse potential)

Settlement value impact: Gabapentinoid dose escalation — starting at 300mg and climbing to 2400mg or higher — creates a documented treatment curve that maps directly to injury severity. Each dose increase represents a clinical determination that the current dose is inadequate, meaning the nerve damage is more severe than initially expected.

[!TIP] When reviewing pharmacy records, note the gabapentinoid dose trajectory. A patient who starts at gabapentin 300mg TID and escalates to 800mg TID over three months has a documented pattern of treatment resistance that powerfully supports a chronic neuropathic pain diagnosis.

SNRIs: Duloxetine and Venlafaxine

Serotonin-norepinephrine reuptake inhibitors serve a dual purpose in PI cases: they treat chronic pain through descending pain inhibition pathways AND treat co-occurring depression, anxiety, and PTSD.

Duloxetine (Cymbalta):

• FDA-approved for chronic musculoskeletal pain, diabetic neuropathy, fibromyalgia, and major depressive disorder
• Dosed 30-120mg daily
• The most commonly prescribed SNRI for chronic PI pain with psychological comorbidity

Venlafaxine (Effexor XR):

• More commonly prescribed for PTSD and anxiety with pain comorbidity
• Dosed 75-225mg daily
• Norepinephrine reuptake increases at higher doses, enhancing pain inhibition

Settlement value impact: An SNRI prescription simultaneously documents two injury dimensions: chronic pain AND psychological injury. A single medication that treats both conditions means the prescriber has determined that the patient's post-accident condition involves intertwined physical and psychological components — strengthening both special and general damage claims.

Prescription Topical Analgesics

Topical prescription analgesics treat localized pain without systemic side effects:

Diclofenac gel (Voltaren Rx):

• Prescription-strength NSAID applied directly to the injury site
• FDA-approved for osteoarthritis; used for localized soft tissue and joint pain

Lidocaine patches (Ztlido, Lidoderm):

• 4-5% lidocaine applied to the painful area
• FDA-approved for postherpetic neuralgia; used for localized neuropathic pain
• Provides targeted nerve block at the application site

Compound topical creams:

• Custom-compounded with combinations of ketamine, gabapentin, baclofen, diclofenac
• Prescribed when commercial topicals are insufficient
• Higher cost reflects the compounding and multiple active ingredients

Settlement value impact: Topical prescriptions document localized pain that is persistent enough to require site-specific treatment. Compound creams, with their multi-drug formulations and higher cost, document particularly complex or treatment-resistant pain.

CGRP Agents for Post-Traumatic Migraine

Calcitonin gene-related peptide (CGRP) inhibitors have transformed post-traumatic migraine treatment:

Injectables (monthly or quarterly):

• Aimovig (erenumab) — monthly subcutaneous injection
• Ajovy (fremanezumab) — monthly or quarterly injection
• Emgality (galcanezumab) — monthly injection

Oral agents:

• Qulipta (atogepant) — daily oral preventive
• Nurtec ODT (rimegepant) — acute treatment and prevention

As Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist explains, "CGRP agents are among the most expensive medications in PI pharmacy records, often exceeding $700 per monthly fill. Their presence documents that the patient developed post-traumatic migraines severe enough to warrant specialty migraine therapy — a significant injury complication."

Settlement value impact: CGRP prescriptions add substantial pharmacy specials while documenting a specific, serious neurological injury complication. Post-traumatic migraine is a recognized sequela of TBI and whiplash, and treatment with a CGRP agent confirms the diagnosis with objective pharmacy evidence.

[!KEY] Each non-opioid drug class in the pharmacy record documents a different injury dimension: Journavx for acute nociceptive pain, gabapentinoids for nerve damage, SNRIs for chronic pain with psychological injury, topicals for localized persistent pain, and CGRP agents for post-traumatic migraine. Together, they build a multi-dimensional picture of injury severity that is far more persuasive than any single medication alone.

Muscle Relaxants: Often Overlooked but Important

While not strictly "pain" medications, muscle relaxants are prescribed for the protective spasm that accompanies most musculoskeletal PI injuries:

• Cyclobenzaprine (Flexeril) — most common; sedating; documents significant spasm
• Methocarbamol (Robaxin) — less sedating; often used when the patient needs to function
• Tizanidine (Zanaflex) — alpha-2 agonist; used for spasticity from spinal injury
• Metaxalone (Skelaxin) — least sedating; brand-name cost adds to pharmacy specials

Building the Non-Opioid Case Narrative

For the demand package, present the non-opioid medication record as a treatment progression that documents the full complexity of the injury:

1. Acute phase: Journavx + NSAIDs + muscle relaxants (documents immediate moderate-to-severe pain)
2. Subacute phase: Gabapentinoid initiation (documents nerve damage becoming apparent)
3. Chronic phase: SNRI addition (documents chronic pain with psychological impact)
4. Specialty intervention: CGRP agents or compound topicals (documents treatment resistance and specific complications)

LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report for every case, providing pharmacist-signed documentation for demand packages that organizes this medication timeline into a clinical narrative adjusters can follow.

If your clients need any of these non-opioid medications following a personal injury, LienScripts provides pharmacy lien coverage for every drug class discussed in this guide — with no upfront cost and repayment from settlement proceeds.

Related Resources

• Journavx (Suzetrigine): The First New Pain Mechanism in Decades
• Gabapentin vs. Pregabalin for Personal Injury Cases
• CGRP Medications for Post-Traumatic Migraine
• Duloxetine for Chronic Pain After an Accident
• Non-Opioid Pain Management After an Accident: 2025 Guide